ASCO20: completing the circle for EGFR-directed therapies

Written by Shawn Jindal MD and Balazs Halmos MD (Montefiore Medical Center, NY, USA)

Over the last 15 years, we have seen a tremendous growth in our ability to tailor cancer therapies based on tumor biomarkers – aptly named ‘precision oncology.’ Non-small-cell lung cancer has been at the forefront of the precision oncology movement, starting with the original discovery of recurrent EGFR mutations in patients’ tumors who respond to first-generation EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib [1]. To date, we have eight validated molecular biomarkers to guide targeted treatment selection (besides EGFR, we have ALK/ROS/NTRK translocations, B-Raf V600E and ErbB2 mutations, as well as MET exon 14 skipping alteration), and...

To view this content, please register now for access

It's completely free